News Breaks |
|
|
| September 4, 2012 |
| 08:12 EDT |  | ALNY | Alnylam presents complete results from Phase IIb trial with ALN-RSV01
Alnylam Pharmaceuticals announced complete results from its Phase IIb trial with ALN-RSV01 for the treatment of respiratory syncytial virus infection in lung transplant patients. The data were presented at the European Respiratory Society’s Annual Congress held in Vienna, September 1-5, 2012. As reported previously, the study narrowly missed the primary endpoint of reduced day 180 BOS in an “intent-to-treat” analysis of confirmed RSV infected patients, but achieved statistically significant reductions in prospectively defined analyses of ITTc patients with their “last observation carried forward”, and of ITTc patients treated “per protocol”. At the ERS meeting, new results were presented on secondary endpoints and certain post-hoc analyses that support the efficacy of ALN-RSV01 in this setting. Further, and as reported earlier, ALN-RSV01 was found to be generally safe and well tolerated in the study. Alnylam plans to discuss these complete results with U.S. and European regulatory authorities, and communicate future development plans for ALN-RSV01 at year’s end. |
|
|
News For ALNY From The Last 14 Days Check below for free stories on ALNY the last two weeks. |
|
|
| May 24, 2013 |
| 10:04 EDT |  | ALNY | On The Fly: Analyst Initiation Summary
 Subscribe for More Information |
|
| 05:47 EDT | | ALNY | Alnylam initiated with a Buy at Deutsche Bank
Subscribe for More Information |
|
| May 22, 2013 |
| 11:53 EDT |  | ALNY | High option volume stocks: UAN MYL ALNY SKS XIDE
Subscribe for More Information |
|
| 07:28 EDT |  | ALNY | UBS to host a conference
Global Healthcare Services Conference is being held in New York on May 20-22 with webcasted company presentations to begin on May 22 at 8 am; not all company presentations may be webcasted. Webcast Link |
|
| May 17, 2013 |
| 08:04 EDT | | ALNY | Alnylam announces proof-of-concept data from RNAi program
Subscribe for More Information |
|
| May 16, 2013 |
| 07:29 EDT | | ALNY | Leerink to host a bus tour
Boston Biopharma Bus Tour travels throughout Boston on May 16-17. |
|
| May 14, 2013 |
| 08:43 EDT |  | ALNY | Alnylam has multiple upcoming positive catalysts, says JMP Securities
JMP Securities believes that Alnylam will have multiple positive data catalysts over the next two months. The firm thinks that upcoming data and presentations will enhance the company's positioning and perception of its pipeline, and it keeps an Outperform rating on the shares. |
|
|
|
|
|
